Clinical Trial Update: A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

View source ↗

Summary

A completed post-marketing surveillance study evaluating cetuximab in patients with squamous cell carcinoma of the head and neck.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Carcinoma, Squamous Cell of Head and Neck | Status: COMPLETED